|
Insulin Glargine recombinant
resources
|
|
|
|
|
|
DRUG INFO
Insulin Glargine recombinant
Drug Name:
Insulin Glargine recombinant
Indication: For treatment of diabetes (type I and II)
Pharmacology: Used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat.
Mechanism Of Action: Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.
Drug Category: Hypoglycemic Agents; insulins (68:20.08)
Brand Names/Synonyms: Lantus; Lantus
Dosage Forms: SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Recombinant human insulin
Chemical Formula: C267H408N72O77S6 >B chain
Half Life: 30 hours (mammalian reticulocytes, in vitro)
Drug Type: Approved Drug
# Accession No: BIOD00045
CAS Registry Number: 160337-95-1
|
|
|
|
|
|
Insulin Glargine recombinant News
(When available)
SciGen establishes China manufacturing facility Dec 14, 2005
In-PharmaTechnologist.com, ...with 54 per cent (Humalog and Humulin, each grossing about $1 billion) and Sanofi-Aventis, with a 16 per cent share of the worldwide market (Lantus, about $0.8 ...
|
|
|
